Advancements in the Treatment of Desmoid Tumors

Chandrajit Raut, MD, provides an overview of the landscape surrounding desmoid tumors, highlighting associated epidemiology and common characteristics.

Marilyn Bui, MD, PhD, explores the pathogenesis and diagnosis of desmoid tumors, emphasizing the significance of a multidisciplinary diagnostic approach.

Mark Agulnik, MD, discusses signs and symptoms commonly presenting with desmoid tumors and their impact on quality of life for patients.

A panel of oncology experts examine the significance of employing active surveillance as a primary strategy in the treatment of desmoid tumors, providing expert insights into this approach.

Chandrajit Raut, MD, shares expert insights into the evolving role of surgical strategies for desmoid tumor management, emphasizing essential factors in patient selection.

Chandrajit Raut, MD, explores the role of radiotherapy and other locoregional strategies in desmoid tumor management, highlighting the emerging role of cryoablation and HIFU.

Mark Agulnik, MD, gives a summary of approaches to systemic therapy in the management of desmoid tumors, highlighting the diminishing role of chemotherapy and the shift towards targeted therapies.

Jonathan Trent, MD, PhD, discusses the role of approaches using low-dose and conventional chemotherapy, emphasizing key consideration factors for patient selection.

A panel of oncology experts provides insights into the management of desmoid tumors in women, focusing on special considerations for pregnancy and contraception.

Mark Agulnik, MD, examines the mechanism of action of nirogacestat, emphasizing the impact of ϒ-secretase inhibition on NOTCH pathway signaling.

Jonathan Trent, MD, PhD, discusses the rationale and design of the DeFi study, instrumental in the FDA approval of nirogacestat, and explores key efficacy and safety findings from this research.

A panel of oncology experts discuss the impact of nirogacestat on pain symptoms and quality of life indicators for individuals with desmoid tumors, as well as the possible effects on ovarian function.

Expert oncologists discuss the recent approval of nirogacestat for the treatment of desmoid tumors and explore its impact on clinical practice and the future treatment landscape.

A panel of oncology experts provides insights into the future outlook for desmoid tumor treatment, discussing anticipated developments in the field.